Company Profile

Pacific Biosciences of California Inc (AKA: NFI~Nanofluidics Inc~Pacific Biosciences~PacBio)
Profile last edited on: 4/21/21      CAGE: 49H66      UEI: CP22V46XYQK6

Business Identifier: Sequencing systems to resolve genetically complex problems
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1380 Willow Road
Menlo Park, CA 94025
Location: Single
Congr. District: 18
County: San Mateo

Public Profile

Originally doing business as Nanofluidics, Pacific Biosciences is focused to transforming the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research. Anchored in work undertaken while SBIR-involved as Nanofluidics, the Company has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, Pacific Biosciences has created a powerful technology platform called single molecule, real-time, or SMRT™, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform the understanding of biological systems by providing a window into these systems that has not previously been open for scientific study. Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio® RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological syste

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $149,176
Project Title: Fmr 1-Sls: Improving Fragile X Diagnosis Using Amplification-Free Single Locus Ta
2003 1 NIH $110,298
Project Title: Zero-Mode Waveguides for Single-Molecule Detection
2002 1 NIH $199,783
Project Title: Nanofluidics-based DNA Screening Device

Key People / Management

  Joseph Bonventre -- Former President

  Christian O Henry -- CEO & President

  Michael Hunkapiller -- President and CEO

  Lori Aro -- SeniorDirector Clinical Genomics, Global Vertical Markteting

  Susan K Barnes -- CFO and SVP

  Kevin Corcoran -- SVP Market Development

  Susan Kim -- CFO

  Jonas Korlach -- Chief Scientific Officer

  Michael Phillips -- VP R&D

  Stephen W Turner -- Founder and CTO

  Aaron Wenger